SUMMIT THERAPEUTICS INC (SMMT) Stock Price, Quote, News and Overview
NASDAQ:SMMT - Nasdaq - US86627T1088 - Common Stock - Currency: USD
SMMT Quote, Performance and Key Statistics
18.99
-0.56 (-2.86%)
The current stock price of SMMT is 18.99 USD. In the past month the price decreased by -8.61%. In the past year, price increased by 331.59%.
SMMT Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 20.83 | 372.42B | ||
| AMGN | AMGEN INC | 16.04 | 170.67B | ||
| GILD | GILEAD SCIENCES INC | 25.17 | 144.59B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1674.9 | 124.78B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.3 | 76.35B | ||
| ARGX | ARGENX SE - ADR | 238.59 | 37.26B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.00B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.42B | ||
| BNTX | BIONTECH SE-ADR | N/A | 26.57B | ||
| BIIB | BIOGEN INC | 8.95 | 21.47B | ||
| NTRA | NATERA INC | N/A | 18.68B | ||
| GMAB | GENMAB A/S -SP ADR | 24.96 | 15.06B |
Related stock screener links
About SMMT
Company Profile
Summit Therapeutics, Inc. a biopharmaceutical company, which discovers, develops, and commercializes medicines to treat infectious diseases. The company is headquartered in Miami, Florida and currently employs 105 full-time employees. The company went IPO on 2004-10-14. The firm's development candidate is ivonescimab, a potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. The company develops ivonescimab in non-small cell lung cancer (NSCLC), specifically launching Phase III clinical trials in the indications such as ivonescimab combined with chemotherapy in patients with epidermal growth factor receptor (EGFR)-mutated, locally advanced or metastatic non-squamous NSCLC who have progressed after treatment with a third-generation EGFR tyrosine kinase inhibitor (HARMONi), and ivonescimab combined with chemotherapy in first-line metastatic squamous NSCLC patients (HARMONi-3). Its ivonescimab is engineered with Akeso's Tetrabody technology.
Company Info
SUMMIT THERAPEUTICS INC
601 Brickell Key Drive, Suite 1000
Miami FLORIDA 02142 US
CEO: Robert W. Duggan
Employees: 105
Company Website: https://www.smmttx.com/
Investor Relations: https://www.smmttx.com/investors-and-media/investor-centre/
Phone: 13052032034
SUMMIT THERAPEUTICS INC / SMMT FAQ
What is the stock price of SUMMIT THERAPEUTICS INC today?
The current stock price of SMMT is 18.99 USD. The price decreased by -2.86% in the last trading session.
What is the ticker symbol for SUMMIT THERAPEUTICS INC stock?
The exchange symbol of SUMMIT THERAPEUTICS INC is SMMT and it is listed on the Nasdaq exchange.
On which exchange is SMMT stock listed?
SMMT stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for SUMMIT THERAPEUTICS INC stock?
14 analysts have analysed SMMT and the average price target is 35.32 USD. This implies a price increase of 85.98% is expected in the next year compared to the current price of 18.99. Check the SUMMIT THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is SUMMIT THERAPEUTICS INC worth?
SUMMIT THERAPEUTICS INC (SMMT) has a market capitalization of 14.00B USD. This makes SMMT a Large Cap stock.
How many employees does SUMMIT THERAPEUTICS INC have?
SUMMIT THERAPEUTICS INC (SMMT) currently has 105 employees.
What are the support and resistance levels for SUMMIT THERAPEUTICS INC (SMMT) stock?
SUMMIT THERAPEUTICS INC (SMMT) has a support level at 18.7 and a resistance level at 19.96. Check the full technical report for a detailed analysis of SMMT support and resistance levels.
Should I buy SUMMIT THERAPEUTICS INC (SMMT) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of SMMT, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of SMMT, evaluating the profitability, health, valuation and growth aspects
- SUMMIT THERAPEUTICS INC (SMMT) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- SUMMIT THERAPEUTICS INC (SMMT) Sales and EPS estimates to see what analysts future expectations are.
- SUMMIT THERAPEUTICS INC (SMMT) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- SUMMIT THERAPEUTICS INC (SMMT) Insider and Institutional Ownership to learn about the owners and their transactions.
- SUMMIT THERAPEUTICS INC (SMMT) Stock Chart to make your own analysis
- SUMMIT THERAPEUTICS INC (SMMT) Latest news and press-releases to stay up to date.
Does SUMMIT THERAPEUTICS INC (SMMT) stock pay dividends?
SMMT does not pay a dividend.
When does SUMMIT THERAPEUTICS INC (SMMT) report earnings?
SUMMIT THERAPEUTICS INC (SMMT) will report earnings on 2025-04-29, before the market open.
What is the Price/Earnings (PE) ratio of SUMMIT THERAPEUTICS INC (SMMT)?
SUMMIT THERAPEUTICS INC (SMMT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.31).
What is the Short Interest ratio of SUMMIT THERAPEUTICS INC (SMMT) stock?
The outstanding short interest for SUMMIT THERAPEUTICS INC (SMMT) is 18.6% of its float. Check the ownership tab for more information on the SMMT short interest.
SMMT Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to SMMT. When comparing the yearly performance of all stocks, SMMT is one of the better performing stocks in the market, outperforming 99.16% of all stocks.
SMMT Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to SMMT. SMMT has a great financial health rating, but its profitability evaluates not so good.
SMMT Financial Highlights
Over the last trailing twelve months SMMT reported a non-GAAP Earnings per Share(EPS) of -0.31. The EPS decreased by -106.67% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -50.81% | ||
| ROE | -56.93% | ||
| Debt/Equity | 0 |
SMMT Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to SMMT. The Buy consensus is the average rating of analysts ratings from 14 analysts.